Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity

LAYMAN SUMMARY: HER2 is an oncogenic driver in a subset of breast cancer. Despite the fact that there are the options of several anti-HER2 targeted therapies, most patients with metastatic HER2+ breast cancer die from the disease. Therapies to overcome treatment resistance in the metastatic settings...

Descripción completa

Detalles Bibliográficos
Autores principales: Koirala, Nischal, Dey, Nandini, Aske, Jennifer, De, Pradip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224522/
https://www.ncbi.nlm.nih.gov/pubmed/35742993
http://dx.doi.org/10.3390/ijms23126547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224522/
https://www.ncbi.nlm.nih.gov/pubmed/35742993
http://dx.doi.org/10.3390/ijms23126547

Ejemplares similares